RadiotherapeuticTarget MechanismRadionuclideLigand/CarrierIndicationStatusRadiation Typetarget_mechanism_hfilterisotope_hfilterligand_carrier_hfilterindication_hfilterstatus_hfilterleading_emitter_hfilter
Ac-225-CONV-01-αRead morepsma225acconv-01-%ce%b1prostate-cancerpreclinicalalpha-%ce%b1
Ac-225-DOTATATERead moresomatostatin-receptors225acedotreotatesolid-tumorsin-clinical-developmentalpha-%ce%b1
Ac-225-DOTATOCRead moresomatostatin-receptors225acedotreotideneuroendocrine-tumor-netpreclinicalalpha-%ce%b1
Ac-225-DOTAZOLRead morebones225acn-abone-pain-palliationpreclinicalalpha-%ce%b1
Ac-225-FPI-1434Read moreigf-1r225acfpi-1434solid-tumorsin-clinical-developmentalpha-%ce%b1
Ac-225-Lintuzumab (Ac-225 Actimab-A™), Read morecd33225aclintuzumabacute-myeloid-lymphoma-aml colon-cancerin-clinical-developmentalpha-%ce%b1
Ac-225-PSMA-617Read morepsma225acvipivotideprostate-cancerin-clinical-developmentalpha-%ce%b1
At-211-81C6 mAb (Neuradiab)Read moretenascin211at81c6-mabbrain-canceron-hold-or-discontinuedalpha-%ce%b1
At-211-MX35-F(ab’)-2Read moreovcar-3211atmx35-fab2ovarian-cancerin-clinical-developmentalpha-%ce%b1
Bi-213-Lintuzumab (Bi-213 Bismab-A™)Read morecd33213bilintuzumabnon-hodgkins-lymphoma-nhlon-hold-or-discontinuedalpha-%ce%b1
Cu-64-Diasparagine (CuASP)Read moredna64cun-abrain-canceron-hold-or-discontinuedc-e-conversion-electron
Cu-67-SARbisPSMARead morepsma67cupsmaprostate-cancerpreclinicalbeta-%ce%b2
Cu-67-SARTATE, , Read moresomatostatin-receptors67cusartatemeningioma neuroblastoma neuroendocrine-tumor-netpreclinicalbeta-%ce%b2
Er-169-Erbium CitrateRead morebrachytherapy169ern-arheumatologymarketedbeta-%ce%b2
Ho-166- MicrospheresRead morebrachytherapy166hon-ahepatocarcinomamarketedbeta-%ce%b2
Ho-166-Chitosan, , , , Read morebrachytherapy166hon-ahepatocarcinoma melanoma prostate-cancer rheumatology solid-tumorsmarketedbeta-%ce%b2
Ho-166-PhytateRead morebrachytherapy166hon-arheumatologyon-hold-or-discontinuedbeta-%ce%b2
I-131-81C6 mAb (Neuradiab™)Read moretenascin131i81c6-mabbrain-canceron-hold-or-discontinuedbeta-%ce%b2
I-131-Apamistamab (Iomab-B™), , , , Read morecd45131iapamistamabacute-lymphoblastic-leukemia-all acute-myeloid-lymphoma-aml hodgkins-lymphoma-hl myelodysplastic-syndrome-mds non-hodgkins-lymphoma-nhlin-clinical-developmentbeta-%ce%b2
I-131-BA52Read moremelanin131iba52melanomaon-hold-or-discontinuedbeta-%ce%b2
I-131-CAM-H2Read moreher2131isgmibbreast-cancerin-clinical-developmentbeta-%ce%b2
I-131-chTNT (Vivatuxin), , Read moredna131iderlotuximabbrain-cancer hepatocarcinoma lung-cancermarketedbeta-%ce%b2
I-131-CLR 131Read morepi3k131iclr-131multiple-myelomain-clinical-developmentbeta-%ce%b2
I-131-ICF01012Read moremelanin131iicf01012melanomapreclinicalbeta-%ce%b2
I-131-Iobenguane (MIBG), , Read moreadrenergic-tissues131iiobenguaneneuroblastoma neuroendocrine-tumor-net pheochromocytomazmarketedbeta-%ce%b2
I-131-LipiodolRead morefatty-acid-containing-tissues131ilipiodolhepatocarcinomamarketedbeta-%ce%b2
I-131-MetuximabRead morecd147131in-ahepatocarcinomamarketedbeta-%ce%b2
I-131-Naxitamab, Read moregd2131inaxitamabneuroblastoma neuroendocrine-tumor-netin-clinical-developmentbeta-%ce%b2
I-131-Omburtamab, , Read moreb7-h3-cd276131iomburtamabneuroblastoma neuroendocrine-tumor-net soft-tissue-cancerin-clinical-developmentbeta-%ce%b2
I-131-RPS-001Read morepsma131irps-001prostate-cancerin-clinical-developmentbeta-%ce%b2
I-131-Sodium Iodide, Read morethyroid-tissues131in-ahead-and-neck-cancer thyroid-cancermarketedbeta-%ce%b2
I-131-TLX-101Read morelat-1131iphenylalaninebrain-cancerin-clinical-developmentbeta-%ce%b2
I-131-TM601, Read moreannexin131ichlorotoxinbrain-cancer melanomaon-hold-or-discontinuedbeta-%ce%b2
I-131-Tositumomab (Bexxar®)Read morecd20131itositumomabnon-hodgkins-lymphoma-nhlon-hold-or-discontinuedbeta-%ce%b2
I-131-WeimeishengRead moredna131iweimeishenglung-cancermarketedbeta-%ce%b2
Lu-177-CTT-1403Read morepsma177luctt-1403prostate-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-Debio-1124Read morecck2r177luminigastrin-psig-2thyroid-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-DOTA-EB-TATERead moresomatostatin-receptors177lueb-tateneuroendocrine-tumor-netin-clinical-developmentbeta-%ce%b2
Lu-177-DOTAZOLRead morebones177lun-aprostate-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-DTPA-Omburtamab, Read moren-a177lun-abrain-cancer medulloblastomain-clinical-developmentbeta-%ce%b2
Lu-177-EB-PSMA-617Read morepsma177lueb-psma-617prostate-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-Edotreotide (Solucin®)Read moresomatostatin-receptors177luedotreotideneuroendocrine-tumor-netin-clinical-developmentbeta-%ce%b2
Lu-177-EDTMPRead morebones177lun-abone-pain-palliationmarketedbeta-%ce%b2
Lu-177-FAP-2286Read morefibroblasts177lufap-2286solid-tumorsin-clinical-developmentbeta-%ce%b2
Lu-177-FAPI-04Read morefibroblasts177lufapi-04solid-tumorspreclinicalbeta-%ce%b2
Lu-177-IPN-01087Read morentsr1177luipn-01087pancreas-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-IPN-1072 (Lu-177-OPS201 – Lu-177-Satoreotide)Read moresomatostatin-receptors177lusatoreotideneuroendocrine-tumor-netin-clinical-developmentbeta-%ce%b2
Lu-177-iPSMARead morepsma177luipsmaprostate-cancerpreclinicalbeta-%ce%b2
Lu-177-Lilotomab Satetraxetan (Betalutin)Read morecd37177lun-anon-hodgkins-lymphoma-nhlin-clinical-developmentbeta-%ce%b2
Lu-177-MVT-1075Read moreslea177lumvt-1075pancreas-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-Oxodotreotide (Lutathera®)Read moresomatostatin-receptors177luoxodotreotideneuroendocrine-tumor-netmarketedbeta-%ce%b2
Lu-177-Pentixather, Read morecxcr4177lupentixathermultiple-myeloma solid-tumorsin-clinical-developmentbeta-%ce%b2
Lu-177-PNT2002Read morepsma177lupsma-itprostate-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-PSMA-617 (Pluvicto™)Read morepsma177luvipivotideprostate-cancermarketedbeta-%ce%b2
Lu-177-PSMA-R2Read morepsma177lupsma-r2prostate-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-RM2Read moregrpr177lubombesinprostate-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-ST2210 (IART – Lu-177 DOTA-Biotin), Read moreavidin177lubiotinbreast-cancer colon-canceron-hold-or-discontinuedbeta-%ce%b2
Lu-177-TLX250Read morecaix177lugirentuximabkidney-cancerin-clinical-developmentbeta-%ce%b2
Lu-177-TLX591Read morepsma177lurosopatamabprostate-cancerin-clinical-developmentbeta-%ce%b2
P-32-Colloidal Chromic Phosphate, , Read morebones32pn-abrain-cancer rheumatology solid-tumorsmarketedbeta-%ce%b2
P-32-OncoSilRead morebrachytherapy32pn-apancreas-cancermarketedbeta-%ce%b2
P-32-Sodium Phosphate, Read morebones32pn-abone-pain-palliation polycythemia-veramarketedbeta-%ce%b2
Pb-212-DOTAMTATERead moresomatostatin-receptors212pbdotamtateneuroendocrine-tumor-netin-clinical-developmentalpha-%ce%b1
Pb-212-VMT01Read moremcr1212pbvmt01melanomapreclinicalalpha-%ce%b1
Ra-223-Radium DichlorideRead morebones223ran-abone-pain-palliationmarketedalpha-%ce%b1
Ra-224-Radium Chloride (224-SpondylAT®)Read morebrachytherapy224ran-aankylosing-spondylitison-hold-or-discontinuedalpha-%ce%b1
Ra-224-RadSpherin, Read morebrachytherapy224ran-acolon-cancer ovarian-cancerin-clinical-developmentalpha-%ce%b1
Re-186-Rhenium Etidronate (HEDP)Read morebones186ren-abone-pain-palliationmarketedbeta-%ce%b2
Re-186-Rhenium SulfideRead morebrachytherapy186ren-arheumatologymarketedbeta-%ce%b2
Re-188-Dendrimer (ImDendrim)Read morebrachytherapy188rehepatocarcinomapreclinicalbeta-%ce%b2
Re-188-Etidronate (HEDP), Read morebones188ren-abone-pain-palliation rheumatologymarketedbeta-%ce%b2
Re-188-P2045 (Tozaride), Read moresomatostatin-receptors188retozaridelung-cancer pancreas-cancerin-clinical-developmentbeta-%ce%b2
Re-188-Rhenium LipiodolRead morefatty-acid-containing-tissues188relipiodolhepatocarcinomamarketedbeta-%ce%b2
Re-188-Rhenium SulfideRead morebrachytherapy188ren-arheumatologymarketedbeta-%ce%b2
Sm-153-DOTMP (CycloSAM)Read morebones153smn-abone-pain-palliationin-clinical-developmentbeta-%ce%b2
Sm-153-Lexidronam (EDTMP)Read morebones153smn-abone-pain-palliationmarketedbeta-%ce%b2
Sm-153-Oxabiphor (ETMP)Read morebones153smn-abone-pain-palliationmarketedbeta-%ce%b2
Sn-117m-DOTA-Annexin-V, Read moreannexin117msnannexin-vrheumatology vulnerable-plaquein-clinical-developmentc-e-conversion-electron
Sn-117m-DTPARead morebones117msnn-abone-pain-palliationin-clinical-developmentc-e-conversion-electron
Sn-117m-HTC (Synovetin)Read morebrachytherapy117msnn-arheumatologymarketedc-e-conversion-electron
Sr-89-Strontium ChlorideRead morebones89srn-abone-pain-palliationmarketedbeta-%ce%b2
Th-227-Anetumab corixetan, Read moremesothelin227thanetumabovarian-cancer solid-tumorspreclinicalalpha-%ce%b1
Th-227-Epratuzumab (Th-227-BAY1862864)Read morecd22227thepratuzumabnon-hodgkins-lymphoma-nhlon-hold-or-discontinuedalpha-%ce%b1
Th-227-PSMA-TTCRead morepsma227thpsmaprostate-cancerpreclinicalalpha-%ce%b1
Y-90-BesilesomabRead morecd6690ybesilesomabamyloidosisin-clinical-developmentbeta-%ce%b2
Y-90-Daclizumab (HAT), Read morecd2590ydaclizumableukemia non-hodgkins-lymphoma-nhlon-hold-or-discontinuedbeta-%ce%b2
Y-90-DOTA-FF-21101, , Read moreigf-1r90yp-cadherinbiliary-tract-cancer head-and-neck-cancer ovarian-cancerpreclinicalbeta-%ce%b2
Y-90-DOTALAN (Lanreotide)Read moresomatostatin-receptors90yedotreotideneuroendocrine-tumor-neton-hold-or-discontinuedbeta-%ce%b2
Y-90-DOTATOC (Edotreotide)Read moresomatostatin-receptors90yedotreotideneuroendocrine-tumor-neton-hold-or-discontinuedbeta-%ce%b2
Y-90-Epratuzumab TetratexanRead morecd2290yepratuzumabnon-hodgkins-lymphoma-nhlon-hold-or-discontinuedbeta-%ce%b2
Y-90-FerritargRead moreferritin90yferritarghodgkins-lymphoma-hlon-hold-or-discontinuedbeta-%ce%b2
Y-90-Ibritumomab Tiuxetan, , Read moreigf-1r90yibritumomabbiliary-tract-cancer head-and-neck-cancer ovarian-cancerpreclinicalbeta-%ce%b2
Y-90-IsoPet – Y-90-RadioGelRead morebrachytherapy90yn-asolid-tumorsmarketedbeta-%ce%b2
Y-90-MicrospheresRead morebrachytherapy90yn-ahepatocarcinomamarketedbeta-%ce%b2
Y-90-OPS201 (SOMTher®)Read moresomatostatin-receptors90yops201neuroendocrine-tumor-neton-hold-or-discontinuedbeta-%ce%b2
Y-90-Yttrium CitrateRead morebrachytherapy90yn-arheumatologymarketedbeta-%ce%b2

Radiopharmaceuticals for Therapy

Search our list of radiopharmaceuticals

Nuclear medicine covers the area of a medical practice based on injected radioactive substances, called radiopharmaceuticals, which can be applied for diagnosis (radiodiagnostics) or therapy (radiotherapeutics), or both (radiotheranostics).

The radiolabeled product, a substance containing a radioactive isotope or radionuclide, travels through the body up to reaching its target. Thanks to a vector, on which this radionuclide is grafted, it reaches and accumulates in a specific biological tissue or an organ. This molecule is then useful to locate the targeted tissue or organ (diagnosis), to initiate the destruction of these cells (therapy), or both depending upon the type of attached radionuclide.

The term radiotracer refers to the notion of minute (trace) amounts of the substances in use, and also to the advantageous ability to “trace” the dissemination of the molecule in the body as a consequence of the linked radioactivity (light). The development of imaging acquisition technology associated with powerful information technology software has resulted in the development of the tomography technology, generating cross sectional images and tri-dimensional pictures.

Some radioactive elements can be used for therapeutic purposes thanks to their different physico-chemical properties; indeed, their short distance ionizing effect leads to cell destruction. The use of these vectors in association with therapy radionuclides, essentially β or α emitters, is called vectorized or metabolic radiotherapy. Such radiolabeled drugs used in therapy are also called radiotherapeutics.

Natural radioactivity first appeared concomitantly to the creation of the Earth, and the radionuclides that can still be found in soil today are in fact long period isotopes or decay nuclides dating from original matter. As a consequence, man has always been exposed to environmental radioactivity, whether from terrestrial or cosmic origin, and of course we continue to find these radionuclides in our food and indirectly in each of our body cells.

A radionuclide is a substance that degrades in a very constant manner over time and emits one or several radiations. This degradation or decay is defined by a constant, the period (or half-life) corresponding to the time it takes for half of the remaining substance to disappear. This half-life is specific for each radionuclide.

The type of emitted radiation is also specific for each radionuclide. There are five types of radiation which are of interest to nuclear medicine: for diagnosis purposes, gamma rays (γ) and beta plus (or positron) emissions (β+) have led to the development of respectively the imaging modalities SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography). Beta minus (β–), alpha (α) radiations and soon conversion or Auger electrons are used in metabolic radiotherapy.

Among all the radionuclides with potential in nuclear medicine, we shall remember those that are currently most widely used: Iodine-123 and Technetium-99m as γ emitters, Fluorine-18 and Gallium-68 as β+ emitters, Iodine-131 and Lutetium-177 as β– emitters. Newcomers will include Astatine-211 and Actinium-225 in the alpha-emitting series and Tin-117m as conversion electron emitter.

radiotherapeutics

The list of radiotherapeutics below is intended to be as exhaustive as possible. Despite our best efforts to regularly update the information, the field of radiotherapeutics is changing and evolving rapidly. Should you notice any missing molecules or wish to add some elements of precision, please contact us.